Replies to post #80964 on Biotech Values

[DewDiligence]

AMGN:

Perlmutter is doing marketing for Amgen now? Well, he failed at R&D, so why not?

Do you have an axe to grind with Perlmutter and AMGN? I’m asking because I did not see anything unreasonable in Perlmutter’s quote in the article posted by genisi (#msg-39386685); to the contrary, I thought the Business Week author was harping on a problem that does not exist. Here’s the relevant excerpt:

…denosumab is not the type of product patients can inject themselves, so doctors will have to prod them to come into the office twice a year. That could be a hard sell, especially when physicians have the option of prescribing inexpensive pills. Roger Perlmutter, Amgen's vice-president of research and development, isn't worried. "Most elderly people are seeing a doctor every six months anyway," Perlmutter said in a June interview.

I would argue that the need for patients to schedule an office visit every six months will make doctors more likely to prescribe D-mab.

Last time I checked, doctors were still getting paid for office visits, although Congress might have changed that by now :- )